Categories
Health

COVID-19: Glenmark launches medicine at Rs 103 per tablet

Glenmark was the first company in India to receive the drug regulator’s approval to conduct phase-3 clinical trial of Favipiravir antiviral tablets for COVID-19 patients

Glenmark Pharmaceuticals Ltd. on Saturday said it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate COVID-19 at a price of about Rs 103 per tablet.

The drug will be available as a 200 mg tablet at a maximum retail price of Rs 3,500 for a strip of 34 tablets, the drugmaker said. FabiFlu is the first oral favipiravir-approved medication in India for the treatment of COVID-19, it said in a statement. It is a prescription-based medication, with recommended dose being 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14, it said.

The recommended dose of Favipiravir is 1,800 mg twice daily on day one, followed by 800 mg twice daily up to day 14. It is a prescription-based medicine. The drug will be available both through hospitals and the retail channel, Glenmark said.

Also read: COVID-19: Blood group A have a higher risk of infection

The tablets are being produced by the company at its Baddi facility in Himachal Pradesh. The drug will be available both through hospitals and the retail channel, Glenmark said. The Mumbai-based firm had on Friday received the manufacturing and marketing approval from the Drugs Controller General of India.

“This approval comes at a time when cases in India are spiralling like never before, putting a tremendous pressure on our healthcare system,” Glenmark Pharmaceuticals Chairman and MD Glenn Saldanha said in the statement.

The company hopes that the availability of an effective treatment such as FabiFlu will considerably help assuage this pressure, and offer patients in India a much needed and timely therapy option, he added.

Also read: Indian recovery rate from COVID-19 better than global percentage

“Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country,” he added.

Glenmark was the first company in India to receive the drug regulator’s approval to conduct phase-3 clinical trial of Favipiravir antiviral tablets for COVID-19 patients.

Considering a minimum of two strips per patient, Glenmark will be able to provide FabiFlu for about 82,500 patients in the first month itself.

Last month, Glenmark also announced that it is conducting another clinical trial to evaluate the efficacy of two antivirals Favipiravir and Umifenovir as a combination therapy in moderate hospitalised adult COVID-19 patients in India.

India on Saturday saw another record spike of 14,516 new new COVID-19 cases in a single day, pushing the tally to 3,95,048, while the death toll rose to 12,948 with 375 new fatalities, according to Union Health Ministry data.

By Sirf News Network

Ref: ABOUT US

View Archive